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WDR36 variants in East Indian primary open-angle glaucoma
patients
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Purpose: Glaucoma is a heterogeneous group of optic neuropathies with a complex genetic basis. To date, only the
following four genes have been identified: viz. myocilin (MYOC), optineurin (OPTN), WD repeat domain 36 (WDR36),
and  neurotrophin  4  (NTF4).  However,  there  are  conflicting  reports  regarding  the  involvement  of  WDR36  in  the
pathogenesis of primary open-angle glaucoma (POAG). In the Asian population, mutations in WDR36 appear to play a
minor role in POAG pathogenesis but polymorphic variants have been found to be associated with POAG, especially in
patients with high tension glaucoma (HTG). The purpose of this study is to determine the role of WDR36 in East Indian
POAG patients. To date, no other studies have yet examined this role.
Methods: Ten single nucleotide polymorphisms (SNPs; rs1971050, rs1993465, rs13153937, rs10038177, rs11241095,
rs10043631, rs10038058, rs10491424, rs17553936, and rs13186912) spanning almost the entire WDR36 gene were
selected and their association with eastern Indian POAG patients was evaluated. Our study pool consisted of 323 POAG
patients. Of these 116 were patients who had HTG with intraocular perssure (IOP) >21mmHg and 207 were found to be
non-HTG patients (presenting IOP<21mmHg). The study also included 303 participants as controls. The polymorphisms
were genotyped in both the patients and the controls using the PCR-RFLP method. Moreover, the SNP that showed
significant association was validated by DNA sequencing. The haplotypes were obtained using Haploview 4.1 software.
The allele and haplotype frequencies were compared between the patient group and the control group using Pearson’s
χ2 test.
Results: First, we genotyped the selected SNPs in the 323 POAG patients and 119 of the participants in the control group,
in which only rs10038177 (c.710+30C>T) was found to be strongly associated with the HTG cases (OR=2.186; 95%
CI=1.458–3.277; p=1.4×10−4). To increase the significance of the study, the SNP was genotyped in an additional 184 of
the participants in the control group and it was observed that the SNP retained the association (OR=1.216; 95% CI=1.064–
2.306; p=0.002). However, no haplotype was found to have any sustainable association with POAG. Based on the LD
pattern and location of rs10038177, exon 5 of WDR36 was sequenced but no suspected disease-causing variant was
detected.
Conclusions: Our study suggests a possible association between WDR36 SNP in a cohort of eastern Indian POAG patients
who also have high intraocular pressure (IOP). This study needs to be further validated in a larger patient cohort.
Glaucoma is a heterogeneous group of optic neuropathies
with a complex genetic basis [1]. It diminishes vision, often
without any symptoms or warning. After cataract, glaucoma
is the second largest blinding disorder [2]. The latest reports
estimate  that,  in  2010,  60.5  million  people  had  primary
glaucoma. By 2020, this number is estimated to increase to
79.6 million. This could result in bilateral blindness in 8.4
million people in 2010 and 11.2 million people by 2020 [3].
Among the three principle subtypes of glaucoma [4], primary
angle closure glaucoma (PACG) is reported to occur most
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frequently in the Asian and African population [5,6] while
primary open-angle glaucoma (POAG) is the most frequently
occurring subtype in the Western population [7,8]. However,
Raychaudhuri et al. [9] reported that the incidence of POAG
is more frequent than the incident of PACG (10:1) in the
inhabitants of West Bengal (an eastern state of India); this
region is the area in which this current study was conducted.
The complexity of POAG has recently been reviewed in
detail [1,10]. To date, 27 loci has been reported to be linked
with POAG, but only four genes have been identified: viz.
Myocilin (MYOC) [11], Optineurin (OPTN) [12], WD repeat
domain 36 (WDR36) [13], and neurotrophin 4 (NTF4) [14,
15].
However, the articles that have been published following
the discovery of WDR36 as a candidate for POAG suggested
variable levels of involvement of the gene in the pathogenesis
of this disease [16-24].
Most of the studies regarding the involvement of WDR36
in POAG have been conducted on Caucasian populations
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2618[17-20,22,23] and only two studies have been reported on
Asian  populations;  one  study  reported  on  Japanese
participants  [21]  and  the  other  reported  on  Chinese  [16]
participants. In the Japanese study, S664L was identified as
the only disease-causing variant in one out of the 136 HTG
cases. Additionally, that study reported two SNPs (I264V and
c1965–30A>G) to be associated with high tension glaucoma
(HTG) [21]. In the study of the Chinese population, I713V
was found to be the only potential disease-causing variant,
which was identified in three out of the 82 HTG patients.
Furthermore,  a  strong  association  with  IVS+30  C>T
(rs10038177) was observed in the HTG patients [16]. From
these studies, it appears that mutations in WDR36 play a minor
role  in  POAG  pathogenesis  in  Asian  populations  but  the
common  variants  of  WDR36  are  associated  with  POAG,
especially in patients with HTG. We performed a limited
screening of WDR36 based on previous reports and domain
information but, apart from the reported single nucleotide
polymorphisms  (SNPs)  and  one  synonymous  change
(G134G), we failed to identify any mutation in this gene
[25]. Therefore, we investigated the role of WDR36 SNPs in
POAG patients and, to the best of our knowledge, no study on
the role of this gene has yet been conducted on East Indian
POAG patients.
METHODS
Selection of study subjects: The patients with POAG and the
control subjects were recruited for the study from Dristipradip
Eye Clinic, Kolkata (West Bengal, India). The individuals
speak Bengali and belong to the Indo-European linguistic
group. The patient cohort consisted of 323 POAG patients
among which 116 were considered to have HTG and presented
with intraocular pressure (IOP) >21 mmHg and 207 were
considered to be non-HTG (with presenting IOP<21 mmHg).
Diagnosis of POAG involved clinical, ocular, and systemic
examinations.  IOP  was  measured  using  Goldmann
applanation  tonometry  (Haag-Streit,  Inc.  Mason,  OH)
followed  by  pachymetry  (Ocuscan  A,  Alcon,  TX).  A
Goldmann  3-mirror  gonioscope  (Ocular  Instrument,
Bellevue, WA) was used to assess the angles of the anterior
chamber and the optic disc. The optic disc was also evaluated
with a +78 D lens. Automated threshold field analysis was
conducted using the Humphrey Field Analyzer II (Carl Zeiss,
Dublin,  CA).  The  retinal  nerve  fiber  layer  (RNFL)  was
investigated using scanning laser polarimetry (SLP) with a
variable  corneal  compensation  technique  (GDx-Vcc;  Carl
Zeiss, Dublin, CA).
The suspicion of POAG was raised by the presence of
increased intraocular pressure above 21 mmHg, significant
cupping of the optic disc (>0.7), with or without peripapillary
changes, and the presence of a clinically open angle (angle of
the anterior chamber) on the gonioscopy. POAG was further
confirmed by typical reproducible visual field changes, viz,
arcuate, Bjerrum, Seidel, paracentral and annular scotoma
with nasal steps, and scanning laser polarimetry for RNFL
analysis (nerve fiber Indicator>30). RNFL analysis was used
to  identify  the  pre-perimetric  cases.  Those  patients  were
categorized  as  the  HTG  patients.  The  non-HTG  group  of
patients who had an IOP of less than 21 mmHg on presentation
but had cupping of the optic disc, showed RNFL loss as
diagnosed by SLP and visual field changes characteristic of
POAG. In each case, the IOP was corrected for central corneal
thickness (CCT). Thus, the patient pool consisted of 323 adult
onset open-angle glaucoma cases. The age at diagnosis ranged
from  41  to  88  years,  with  a  mean±standard  deviation  of
63.5±10.4 years. Table 1 provides the distribution of age and
gender  for  both  the  patient  group  and  the  control  group.
Individuals with any history of inflammation or ocular trauma
(past or present) and ocular hypertension were excluded from
this study.
In this study, a total of 303 participants in the control
group  were  recruited  in  two  phases.  For  119  of  the  303
controls, all the 10 SNPs were genotyped in the first phase.
TABLE 1. DISTRIBUTION OF AGE AND GENDER IN PATIENT AND CONTROL COHORTS.
Study phase Patient
Subgroup
Number of
patients
Average
age of
patients
(±SD)
Number of
controls
Average
age of
controls
(±SD)
p- value Gender
distribution in
patient
Gender
distribution in
control
p-value
Phase 1* POAG 323 63.5±10 119 57.3±9.7 <0.0001 M-57%,
F-43%
M-50.5%,
F-49.5%
0.21
Phase 1* Non-HTG 207 65±10 119 57.3±9.7 <0.0001 M-61%,
F-39%
M-50.5%,
F-49.5%
0.06
Phase 1* HTG 116 60±10 119 57.3±9.7 0.0506 M-50%,
F-50%
M-50.5%,
F-49.5%
0.95
Phase 2# HTG 116 60±10 303 50.5±10 <0.0001 M-50%,
F-50%
M-55%,
F-45%
0.31
        *In  phase  1  of  the  study,  a  total  10  SNPs  (rs1971050,  rs1993465,  rs13153937,  rs10038177,  rs11241095,  rs10043631,
         rs10038058, rs10491424, rs17553936, and rs13186912) were genotyped in 323 POAG patients (207 non-HTG, 116HTG) and
         119 controls. #In phase 2 of the study only the SNP (rs10038177) found significantly associated in the first phase was genotyped
         in an additional 184 controls for providing additional power to the study.
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2619An additional 184 controls were genotyped for rs10038177 in
the second phase. The controls were selected based on criteria
which included: age >40 years (mean age±SD, 50.5±10 years;
Table  1);  no  family  history  of  glaucoma  or  ocular
hypertension; IOP less than 20 mmHg in both eyes in at least
one of their last two checkups; CCT greater than 500 μm in
both  eyes;  no  visual  field  defect;  normal  scanning  laser
polarimeter parameters (i.e., a  good    yellowish  “bow-tie”    
scan pattern, a deviation map within the normal limit, a good
double-hump  pattern  in  the  conduction  map,  temporal-
superior-nasal-inferior-temporal (TSNIT) parameters within
the normal limit, a nerve fiber indicator (index) <30 for both
eyes); cup discs that were physiologic and similar in both eyes;
a cup-to-disc ratio <0.2; no defect in disc rim or margin; and
no sphincter hemorrhage around the disc. Individuals with
high myopia, diabetes, and hypertension were excluded from
the control group. The study protocol adhered to the tenets of
the  Declaration  of  Helsinki  and  was  approved  by  the
Institutional Review Board.
Collection of blood samples and genomic DNA preparation:
Eight milliliters of peripheral blood was collected with EDTA
from the POAG patients and the patients without POAG with
their written consent. Genomic DNA was prepared from fresh
whole blood using the PAX gene blood DNA isolation kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
protocol. The DNA was dissolved in TE (10 mM Tris-HCl,
1mM EDTA, pH 8.0).
Genotyping:  Genotyping  of  the  patients  and  the  control
samples  was  conducted  using  PCR-RFLP  methods.  The
sequences for primers used in PCR and the details of the RFLP
analysis are shown in Table 2. The PCR conditions were as
follows: an initial denaturation at 95 °C for 4 min followed by
35 cycles of 30 s of denaturation at 95 °C, 30 s of annealing
at 50–62 °C and 30 s of extension at 72 °C. This was followed
by a final extension at 72 °C for 4 min. All the PCR products
were detected on a 6% polyacrylamide gel with ethidium-
bromide  staining.  The  PCR  products  were  subjected  to
restriction  digestion  with  appropriate  enzymes  from  NEB
(New England Biolabs, Inc. Beverly, MA) for 3 h at optimum
TABLE 2. PCR PRIMERS, ANNEALING TEMPERATURE AND RFLP PATTERN FOR GENOTYPING OF WDR36 SNPS.
SNP ID and location in the gene Primer sequences Annealing
temperature
Restriction
enzyme
RFLP pattern
rs1971050 (c.330+925 C>T) 5′-GAGGTGAAGAGCAATTGGGTTTCTC-3′ 60 °C AluI C: 203 bp, 35 bp
T: 238 bp
 
5′-GCAGTGTCAGGAAAGACACTGTACC-3′
     
rs1993465 (c.459+183A>G) 5′-TTCTTTACCCAGCACACTCTGGAA-3′ 56 °C HinfI G: 147 bp, 25 bp
A: 172 bp
 
5′-TTTTGAAGAAGGTCTCCAAGTGATT-3′
     
rs13153937 (c.460–112A>G) 5′-GCAGATGAACATGCCTGGTCCCTTA-3′ 58 °C BciVI G: 397 bp
A: 336 bp, 61 bp
 
5′-ACAGGCAAAATCTCTGGCATAG-3′
     
rs10038177 (c.710+30C>T) 5′-GCCTCTCATTTATTTTATTTCTCAAGG-3′ 62 °C AluI C: 338 bp, 120 bp
T: 458 bp
 
5′-CCTCTGATACAGGGGACCAACTG-3′
     
rs11241095(c 772G>A, I264V) 5′-GAGGATGGGATGTTGACTGGCAGA-3′ 50 °C HpaI G: 268 bp, 23 bp
A: 293 bp
 
5′-ATAACTTGACCTGACATAAGGTTAA-3′
     
rs10043631 (c.1494+90C>T) 5′-TCCCTAGTGTCTGAAATATTGGATGC-3′ 50 °C DdeI C: 328 bp, 25 bp 
T: 353 bp
 
5′-TAAAATGTTAAACTACGTTTTCTCA-3′
     
rs10038058 (c.1494+143G>A) 5′-TCTTGTTATACTCAAGGTTTCTCATCA-3′ 50 °C ApoI G: 191 bp, 63 bp
A: 102 bp, 89 bp, 63 bp
  5′-AGAATAGTCTTTTGAACAAATAGTGCTG-3′      
rs10491424 (c.1965–905C>T) 5′-CTATCTCCTCTTAAGTGGTTAATGAATT-3′ 58 °C EcoRI C: 147 bp, 24 bp
T: 171 bp
 
5′-ATGTGGTGGATAAGGCAAGG-3′
     
rs17553936 (c.1965–30A>G) 5′-TGGTGACTTTCTGATCAATGCTGGTG-3′ 62 °C CvIQI G: 308 bp, 120 bp
A: 428 bp
 
5′-TCAAGCAGATGTTGAATCACTCAGA-3′
     
rs13186912 (c.2181A>T;V727V) 5′-GGTGTTTTGGGTCTAGTGATGG-3′ 56 °C BstBI A: 234 bp
T: 210 bp, 24 bp
  5′ -CACTTGGTTCTACTGTTTCTTTCGA-3′      
         The dbSNP reference IDs for each SNP and their location in the genomic region are furnished. Ten SNPs (rs1971050,
         rs1993465, rs13153937, rs10038177, rs11241095, rs10043631, rs10038058, rs10491424, rs17553936, and rs13186912) were
         genotyped in 323 POAG patients (207 non-HTG, 116HTG) and 119 controls by RFLP analysis as mentioned in the Table.
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2620temperatures. The digested products were analyzed on a 6%
polyacrylamide gel and the alleles were scored as described
in Table 2. The fidelity of the allele scoring was examined by
direct sequencing of 10% of the samples in which association
was observed. The results suggested complete concordance
between  the  two  methods.  The  sequencing  reaction  was
conducted  in  a  DNA  sequencer  (ABI  3130XL;  Applied
Biosystems,  Foster  City,  CA)  with  BigDye®  terminator
chemistry.
Bioinformatics  and  statistical  analysis:  The  linkage
disequilibrium (LD) among the 10 SNPs was analyzed using
Haploview  software  (Version  4.1).  Estimated  haplotype
frequencies were obtained by standard E-M algorithm [26].
The odds ratio (95% CI) and the p-value for each haplotype
were  obtained  by  comparing  the  results  with  all  other
combined haplotypes. The allele frequencies of the SNPs and
the haplotypes were compared between patients in the POAG
group and participants in the control group, using Pearson’s
chi square test.The p-values were further corrected using the
Bonferroni  method.  The  distribution  of  age  and  gender
between the patient group and the control group was compared
using an unpaired two-tailed t-test and a two-tailed Z-test to
determine the proportion, respectively.
RESULTS
We selected 10 SNPs (rs1971050, rs1993465, rs13153937,
rs10038177,  rs11241095,  rs10043631,  rs10038058,
rs10491424, rs17553936, and rs13186912) based on previous
reports  of  the  association  between  POAG  and  the  SNP
location, such that the SNPs spans the entire WDR36 gene
(Figure 1). In the first phase of the study, all the SNPs were
genotyped in all 323 of the POAG patients and in 119 of the
controls.
rs10038177 as a risk factor for high tension glaucoma:
Among  the  10  SNPs,  only  rs10038177  (c.710+30C>T)
showed a marginal association with POAG cases (age >40
years)  with  the  C-allele  portraying  risk  (OR=1.569;  95%
CI=1.107–2.225;  p=0.011;  Table  3).  However,  when  the
patient pool was divided into two groups, i.e., HTG and non-
HTG groups based on the presenting IOPs, the SNP showed
a strong association with HTG (OR=2.186; 95% CI=1.458–
3.277; p=1.4×10−4) with C-allele as a risk factor, which was
sustained after applying a Bonferroni correction for multiple
tests (Table 3).
To strengthen the observation made for rs10038177, the
SNP was genotyped in an additional 184 of the 303 total
control group participants so as to match the number of POAG
cases. This SNP was found to retain a strong association with
the HTG patient group (OR=1.216; 95% CI=1.064–2.306;
p=0.002) with an increased number of controls (Table 4). In
the genotype analysis, both CC and a combined genotype of
CC and CT were found to be associated with risk for the HTG
patient group (Table 5). Interestingly, the combined genotype
of CC and CT was found to have a more deleterious effect
(OR=1.789;  95%  CI=1.158–2.763;  p=0.009)  than  the  CC
genotype (OR=2.306; 95% CI=1.180–4.508; p=0.014) alone.
Based on the association data and the extent of the LD
between the different SNPs, the nearest exon of associated
Figure 1. Schematic representation of WDR36 with the location of SNPs selected for the study. The sizes of exons and introns shown in the
illustration are not according to scale.
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2623polymorphism rs10038177 (i.e., exon 5) was sequenced for
any  possible  disease  causing  variant  in  116  of  the  HTG
patients. However, except for the SNP (rs10038177), no other
variant was identified in the region.
Lack of association between POAG and other SNPs in
relation to WDR36: The SNP rs13153937 (c.460–112A>G)
was found to be marginally associated with the non-HTG
patient group (OR=1.486; 95% CI=1.035–2.133; p=0.032)
with ‘G’ as the risk allele. However, the association did not
sustain  after  the  Bonferroni  correction  was  conducted  for
multiple tests. Other SNPs did not show any association with
the POAG patients, the HTG patients, or the patients in the
non-HTG group.
Linkage  disequilibrium  pattern  between  the  SNPs  in
WDR36: With the exception of rs1993465 and rs10038177 in
the HTG and the POAG patient groups, and rs11241095 and
rs17553936 in the POAG and the non-HTG patient groups
(Figure 2), no significant LD was observed between the SNPs.
All the SNPs were found to be in HW equilibrium.
WDR36 haplotype variation among POAG patients and
controls: After the haplotype analysis was conducted, a total
of 24 different types of haplotype were obtained. Among the
different  haplotypes  TGGTATGTAA,  TGATGTGCGT,
TAGCACATAA, and CAGCACATAA were found to have
a frequency of >5% in both the patient and the control groups.
The haplotype TAGCACATAA was found to be associated
with the POAG, the HTG, and the non-HTG groups, but these
associations were not sustained after Bonferroni correction for
multiple testing (Table 6).
DISCUSSION
Despite studies that have examined WDR36’s involvement in
POAG  in  different  population  groups,  no  study  has  yet
reported on the role played by this gene in East Indian patients
with  POAG.  Therefore,  this  study  analyzed  10  SNPs  in
WDR36 and observed that only a single SNP (c.710+30C>T;
rs10038177) was strongly associated with POAG patients
who had high IOP.
With the exception of the HTG patients during the first
phase of the study, a significant difference in the distribution
of  age  between  the  POAG  cases  and  the  controls  was
observed. However, no gender bias was observed (Table 1).
It is difficult to determine the exact age of onset of POAG
because, in many cases, patients seek medical help at an age
that is later than the age of onset of the disease, due to its slow
progression without symptoms. Therefore, in our study we
surrogated the age of onset with the age of diagnosis, which
TABLE 4. ALLELE FREQUENCY OF RS10038177 WITH ADDITIONAL CONTROLS.
Allele Patient
Subgroup
Frequency in Patient
(no. of
Chromosomes)
Frequency in Control
(no. of
Chromosomes)
p-value OR (95% CI) Relative risk (95% CI)
C POAG 0.30 (197) 0.27 (162) 0.141    
  HTG 0.32 (88)   0.002* 1.216 (1.064–2.306) 1.437 (1.139–1.799)
  NON-HTG 0.26 (109)   0.886    
T POAG 0.70 (449) 0.73 (444) 0.141 - -
  HTG 0.68 (144)   0.002 - -
  NON-HTG 0.74(305)   0.886 - -
        rs10038177 (c.710+30C>T) was found to be strongly associated with HTG patient group in the first phase of the study. To
        strengthen the observation, rs10038177 was genotyped in additional 184 controls and the SNP was still found to be strongly
        associated with HTG patient group. *Significant observation; P-value, OR and Relative Risk has been assessed with respect to
        C allele.
TABLE 5. GENOTYPE FREQUENCY OF SNP (RS10038177) SHOWING ASSOCIATION WITH POAG.
Genotype Patient
subgroup
Frequency in
patients (n)
Frequency in
controls (n)
p-value OR (95% CI) Relative risk (95% CI)
TT POAG 0.47 (152) 0.53 (161) 0.129 - -
  HTG 0.39 (045)   0.009 0.559 (0.362–0.864) 0.655 (0.466–0.915)
  NON-HTG 0.52 (107)   0.748 - -
CT POAG 0.45 (145) 0.40 (121) 0.210 - -
  HTG 0.47 (054)   0.219 - -
  NON-HTG 0.44 (091)   0.365 -
CC POAG 0.08 (26) 0.07 (021) 0.596 - -
  HTG 0.14 (017)   0.014* 2.306 (1.180–4.508) 1.722 (1.077–2.487)
  NON-HTG 0.04 (009)   0.223 - -
        *Significant observation. Comparison of the genotype frequencies of rs10038177 among 323 POAG (116 HTG cases and 207
        non-HTG cases) patients and 303 controls revealed biased distribution for the CC genotype (p=0.014) portraying risk for HTG
        patient group.
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2624is likely to result in a representation of a relatively older age
group compared to the age of most patients when onset of the
disease first occurs. Thus, it is likely that the age of patients
based on their age at diagnosis is an overestimation when
compared  to  their  age  at  the  time  of  actual  onset,  which
amplifies the difference of the mean age between the cases
and the controls. Additionally, overall the mean age of the
controls is 50 years and the number of controls is three times
higher compared to the HTG cases. Therefore, we argue that
the significant difference in age between the HTG cases and
the control would not confound our finding.
The  role  of  WDR36  in  POAG  still  remains  elusive;
however, from published literature it is known that this gene
probably plays an important role in cell survival by virtue of
its rRNA processing functions [22,27,28]. Wdr36 has been
hypothesized to maintain the homeostasis of retinal ganglion
cells (RGC) and the mutant protein was found to reduce the
growth  of  RGC  isolated  from  mouse  cells  in  culture.
Furthermore, it led to retinal degeneration in a transgenic
mouse expressing mutant protein. Deletion of WDR36 leads
to pre-implantation embryonic lethality in mice specimens
and  causes  apoptotic  cell  death  in  a  cultured  trabecular
meshwork cell line [29,30].
The  implicated  SNP  (rs10038177)  is  located  in  the
proximity of exon 5. Although in silico analysis did not predict
any aberrant biologic event due to this intronic variant, it
Figure 2. LD pattern (r2) of the ten SNPs in WDR36 in the patient and the control groups. The extent of LD is lowered as the shading lightens
(calculated with Haploview 4.1 using standard color schemes).
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2625seems reasonable that this SNP, in a less likely event, could
directly influence the abnormal gene expression or might be
in LD with other yet unidentified variants, which might be
responsible for influencing the gene function. However, direct
sequencing of WDR36 exon 5 did not yield any new suspect
variant that might be located in the genomic region beyond
the coding sequence investigated.
There are conflicting reports regarding the association of
rs10038177 (c.710+30C>T) with glaucoma [16,18,31]. An
analysis of published data revealed that this SNP was found
to be associated with HTG and JOAG cases in a USA study
[18].  However,  other  studies  focusing  on  Caucasian
populations did not reveal any association between this SNP
and POAG [22,23]. Interestingly, contrary to our observation,
the T-allele has been reported to be associated with HTG-
cases  in  one  study  that  examined  the  Chinese  population
[16],  while  in  another  study  no  association  was  observed
[31].·Such a difference in observation might be due to the
variable influence of multiple other factors associated with
POAG  in  the  population  groups  that  these  two  studies
considered. However, lack of information about the ethnicity
and interrelationship between these populations limits further
analysis of the data.
In conclusion, our study reveals a strong association of a
single SNP (rs10038177) in WDR36 with an HTG patient
cohort.  No  haplotype  was  found  to  have  any  significant
association  with  the  POAG  cases.  However,  these
observations will remain tentative until similar experiments
are conducted on additional and larger cohorts in the same
population  groups;  only  then  can  the  initial  observations
including this study be truly validated.
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